[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Poitiers University Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":645},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,54,0,25,[9,42,73,98,121,144,169,196,224,251,276,299,324,352,377,398,425,445,471,496,522,545,570,594,616],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100492367","early-high-flow-oxygen-therapy-with-nebulized-beta-2-agonist-using-a-vibrating-mesh-for-the-management-of-moderate-to-severe-asthma-exacerbation-in-the-emergency-department-100492367",false,"NCT05691218","Early High-flow Oxygen Therapy With nebuLized Beta-2-agonist Using a Vibrating Mesh for the Management of Moderate to Severe Asthma Exacerbation in the Emergency Department","EOLE","Inclusion Criteria:\n\n* Age equal or over 18 years\n* admitted in an Emergency Department with a clinical suspicion of acute exacerbation of asthma according to the Global Initiative for Asthma (GINA) criteria.\n* with at least one of the following criteria 60mn after a first treatment by beta-2 agonist adrenergic nebulization with 3 x 5 mg of terbutaline:\n\n  * Respiratory rate over 22 breaths\u002Fmin\n  * Peak flow \\\u003C 50% of predictive normal value\n  * SpO2 \\\u003C 95% in room air\n  * Signs of severe asthma exacerbation (at least one criteria):\n\nTalks in word, Agitation, Sits hunched forwards, Accessory muscles in use\n\n* Free subject, without guardianship or curatorship or subordination\n* Patients benefiting from a Social Security scheme or benefiting from it through a third party\n* Informed consent signed by the patient after clear and honest information about the study\n\nExclusion Criteria:\n\n* Acute exacerbation of asthma during the last 30 days\n* Clinical suspicion of acute exacerbation of asthma due to anaphylaxis, pneumothorax, pneumomediastinum, pneumonia or atelectasis.\n* At least ONE of the following serious signs: drowsiness, confusion, auscultatory silence\n* Clinical suspicion of another pathology that could explain the respiratory failure such as heart failure, laryngeal obstruction, pulmonary embolism, etc\n* Patients with neurological (Glasgow \\\u003C 13) or hemodynamical failure (Mean Arterial Pressure \\\u003C 65 mmHg)\n* contraindication to treatment with a beta-2-adrenergic agonist\n* History of hypersensitivity (allergy) to terbutaline or any of the constituents\n* Contraindication to OHD\n* Persons benefiting from enhanced protection, namely minors, persons deprived of their liberty by a judicial or administrative decision, people assessed GIR1 or GIR 2 (AGGIR grid), adults under legal protection\n* Pregnant or breastfeeding women, Women at age to procreate and not using effective contraception","ALL","18 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","Acute exacerbation of asthma represents an acute or sub-acute worsening in symptoms and lung function in patients with asthma. It is characterized by a progressive increase in symptoms of shortness of breath, cough, wheezing, or chest tightness. It is a common diagnosis in patients admitted in an Emergency Department for dyspnoea. Near 10 to 15% of respiratory symptoms in an ED are related to acute exacerbation of asthma.\n\nTreatment of acute exacerbation of asthma associates nebulized beta-2 agonist adrenergic with or without ipratropium bromide, oral corticosteroids and controlled oxygen therapy to maintain SpO2 between 93 and 95%. Treatment in the ED did not vary during last years, including for patients with a lack of efficacy after first line treatment, and exacerbation are always associated with a hospitalisation in 40% of adult patients and with mortality in 1% of hospitalized patients.\n\nVibrating mesh nebulizers are devices using vibration to push drug through the mesh, resulting in the drug nebulization. Vibrating mesh nebulizers have been associated with better pulmonary drug delivery than jet-nebulizers, provide faster improvement in peak expiratory flow and have been associated in retrospective studies with patient prognosis, particularly in terms of throughput time and need for hospitalisation. However, no studies have prospectively compared nebulisation with a vibrating membrane device with standard nebulisation in patients with asthma exacerbation on clinically relevant criteria. Nebulisation with a vibrating membrane device may potentiate the clinical efficacy of short-acting bronchodilators, result in faster and more effective clinical improvement, and be associated with improved short- and medium-term patient outcomes.\n\nHigh-flow nasal cannula heated, and humidified oxygen (HNFO) is a ventilatory support which is commonly used for the management of acute respiratory failure for acute respiratory failure in intensive care units and in emergency departments. HFNO delivers high fraction of inspired oxygen (FiO2), generates a low level of positive pressure and provides washout of dead space in the upper airways, thereby improving mechanical pulmonary properties and unloading inspiratory muscles during ARF. Consequently, HFNO is associated with a decrease in the work of breathing. During asthma exacerbation, HFNO was associated with an improvement in the dyspnea level and in the respiratory rate compared with conventional oxygen therapy. However, HFNO has never been assessed in association with nebulized beta-2 adrenergic agonist.\n\nTo resume, beta-2 adrenergic agonist nebulization with a vibrating mesh nebulizer seems effective, especially compared to standard jet nebulization. In addition, HFNO is a technique that appears to be suitable for the pathophysiological conditions of chronic reversible respiratory failure, and can be used during exacerbations of asthmatic disease. The high flow rate of gas makes it possible to control the FiO2 in order to avoid hyperoxia, to generate a PEEP effect, to reduce the patient's work of breathing and the respiratory resistance, and to avoid the re-inhalation of CO2 by a dead space wash-out.\n\nIn the EOLE study, the investigators propose to compare three therapeutic management strategies. One standard strategy (nebulisation with a jet-nebulizer), and two experimental strategies (nebulisation with a vibrating mesh device, and nebulisation with a vibrating mesh device in association with HFNO).\n\nThe investigators hypothesise that bronchodilator nebulization with a vibrating mesh nebulizer is more effective than jet-nebulizers for the management of patients admitted for asthma exacerbation and non-responders or with lack to efficacy to initial treatment. Furthermore, the investigators also hypothesise that the addition of the physiological effects of HFNO may enhance the efficacy of the treatment.\n\nThe therapeutic effects of nebulisation with a vibrating membrane device alone or with the addition of the physiological effects of HFNO could constitute a new approach to the management of asthma patients, particularly in patients who are insufficiently responsive or non-respondent to initial treatment.",[27,28],"Moderate Asthma Exacerbation","Severe Asthma Exacerbation","RECRUITING","2026-08-18",{"date":32,"type":33},"2026-08-20","ACTUAL",{"date":35,"type":33},"2024-02-19",{"date":37,"type":21},"2028-03-19",{"name":39,"class":40},"Poitiers University Hospital","OTHER",1,{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":4},"100651525","bundle-branch-pacing-to-preserve-ejection-fraction-in-atrial-fibrillation-trial-100651525","NCT07759700","Bundle Branch Pacing to Preserve Ejection Fraction in Atrial Fibrillation Trial","Left Bundle Branch Area Pacing Versus Conventional Right Ventricular Pacing as Initial Strategy for Patients With Permanent Atrial Fibrillation and Preserved Left Ventricular Ejection Fraction Requiring Cardiac Pacing: an Open-label, Multicenter, Randomized Clinical Trial. - the BEAT Study -","BEAT","Inclusion Criteria:\n\n* Age ≥ 18 years and \\\u003C90 years\n* Atrial fibrillation requiring ventricular pacing because of\n\n  1. rapid atrial fibrillation requiring atrioventricular node ablation; or\n  2. slow atrial fibrillation i.e. ≤ 50 bpm on admission ECG).\n* Left ventricular ejection fraction ≥50%.\n* Affiliated person or beneficiary of the French social security scheme\n* Having given their informed consent.\n\nExclusion Criteria:\n\n* Indication for an implantable cardioverter defibrillator.\n* Presence of a mechanical tricuspid valve\n* Any prior attempt at implantation of an implantable cardioverter defibrillator, cardiac resynchronization therapy or LBBA pacing\n* Glomerular filtration rate \\\u003C40 mL\u002Fmin\u002F1,73m2 with CKD-EPI formula\n* Chronic respiratory failure\n* Serious medical condition with life expectancy of \\\u003C2 years\n* Pregnant or breastfeeding women, women of childbearing age who do not have effective contraception (hormonal\u002Fmechanical: per os, injectable, transcutaneous, implantable, intrauterine device, or surgical: tubal ligation, hysterectomy, total oophorectomy)\n* Persons benefiting from enhanced protection, i.e. minors, persons deprived of their liberty by a judicial or administrative decision, persons staying in a health or social institution, adults under legal protection, and finally patients in emergency situations","90 Years",{"count":52,"type":21},642,[24],"The goal of this clinical trial is to learn whether left bundle branch area pacing, a technique designed to activate the heart's natural electrical conduction system, is better than conventional right ventricular pacing in adults with permanent atrial fibrillation, preserved heart pumping function, and a need for a pacemaker.\n\nThe main questions it aims to answer are:\n\nDoes left bundle branch area pacing reduce the risk of death, unplanned hospitalization for heart failure, or the need to replace the initial pacing system with biventricular pacing over 2 years? Does it better preserve heart function and quality of life, without increasing pacemaker-related complications?\n\nResearchers will compare left bundle branch area pacing with conventional right ventricular pacing. A total of 642 participants will be randomly assigned to receive one of these two pacing strategies.\n\nParticipants will:\n\nHave a single-chamber pacemaker implanted using either left bundle branch area pacing or conventional right ventricular pacing Undergo electrocardiograms, echocardiograms, and pacemaker checks during 2 years of follow-up Attend follow-up visits approximately 2, 12, and 24 months after implantation Be contacted by telephone approximately 6 and 18 months after implantation Complete questionnaires about their health and quality of life at the beginning and end of the study",[56,57],"Permanent Atrial Fibrillation","Preserved Ejection Fraction",[59,60,61,62,63],"atrial fibrillation","preserved ejection fraction","heart failure","pacemaker","left-bundle-branch-area pacing","NOT_YET_RECRUITING","2026-08-06",{"date":67,"type":33},"2026-08-12",{"date":69,"type":21},"2026-09-15",{"date":71,"type":21},"2030-08-14",{"name":39,"class":40},{"id":74,"slug":75,"hasResults":12,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":41},"100648695","the-impact-of-telemedicine-using-the-callers-mobile-phone-camera-on-the-quality-of-care-provided-to-adult-patients-contacting-the-15-centre-for-acute-dyspnea-100648695","NCT07726628","The Impact of Telemedicine, Using the Caller's Mobile Phone Camera, on the Quality of Care Provided to Adult Patients Contacting the 15 Centre for Acute Dyspnea","TELEDYS","Inclusion Criteria:\n\n* Patients aged 18 or over\n* Contacting the Emergency Medical Communication Center regarding acute dyspnea, respiratory distress or shortness of breath, as the main reason for the call, regardless of the underlying cause\n* The patient or a bystander must have a mobile phone equipped with a camera and capable of making video calls\n* Emergency inclusion authorized by the emergency physician responsible for medical regulation in accordance with the emergency consent procedure applicable at the time of the call\n\nExclusion Criteria:\n\n* An immediate life-threatening emergency justifying the dispatch of an emergency response team on an automatic basis in accordance with local protocols\n* Patient at the end of life or where a decision to limit treatment is known at the time of the call.\n* Refusal to use telemedicine\n* Lack of a telephone network enabling video consultation.\n* Patient already included in the study.\n* Individuals requiring enhanced protection, namely minors, pregnant or breastfeeding women, persons deprived of their liberty by a judicial or administrative decision, and adults under legal guardianship known at the time of the call",{"count":81,"type":21},778,[24],"Dyspnea is the subjective sensation of difficult or uncomfortable breathing. It accounts for approximately 10% of emergency department visits and 8% of calls to Emergency Medical Communication Centers. Nearly half of patients presenting with dyspnea require hospital admission, 15% require ventilatory support, and approximately 5% die. Early recognition of signs of respiratory severity is therefore essential to accurately assess clinical urgency, guide diagnostic evaluation, and inform appropriate management decisions.\n\nIn France, patients are encouraged to contact an Emergency Medical Communication Centers before presenting to an emergency department. Calls are managed by an emergency physician responsible for medical regulation, who performs a remote clinical assessment and determines the most appropriate level of care. Depending on the clinical evaluation, the physician may provide medical advice, refer the patient to an emergency department, dispatch emergency medical services, or send a physician-staffed mobile intensive care unit for life-threatening emergencies.\n\nThe remote assessment of patients presenting with dyspnea is particularly challenging. The inability to directly observe or examine the patient, combined with the caller's difficulty in accurately describing the clinical situation, may impair the recognition of disease severity and result in inappropriate triage decisions, including under-triage and over-triage :\n\nUnder-triage, characterized by failure to dispatch appropriate emergency resources or to refer the patient to an emergency department when indicated, may delay treatment and increase the risk of adverse outcomes, including mortality.\n\nConversely, over-triage, defined as unnecessary referral to primary care or emergency departments or inappropriate dispatch of emergency resources, contributes to emergency department overcrowding, inefficient use of prehospital resources, and increased healthcare costs.\n\nIn a previous study, we demonstrated that video-assisted medical triage improved emergency physicians' ability to assess the severity of patients presenting with acute dyspnea. This telemedicine tool enables real-time transmission of a live video stream from the caller's smartphone camera to the emergency physician through a secure digital platform, providing direct visualization of the patient's clinical condition. By enhancing remote clinical assessment, video-assisted triage has the potential to reduce both under-triage and over-triage.\n\nIn the present stepped-wedge cluster randomized trial, we hypothesized that incorporating real-time video support into the medical regulation of adult patients contacting an Emergency Medical Communication Centers for acute dyspnea would improve the quality of medical decision-making compared with standard telephone triage alone.",[85],"Dyspnea",[87,88,89],"Telemedecine","Dispatch","Triage","2026-07-21",{"date":92,"type":33},"2026-07-24",{"date":94,"type":21},"2026-11",{"date":96,"type":21},"2027-06",{"name":39,"class":40},{"id":99,"slug":100,"hasResults":12,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":12,"sex":17,"minAge":106,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":4},"100647241","optimising-the-cancer-management-of-older-patients-by-early-and-specific-geriatric-interventions-100647241","NCT07704307","Optimising the Cancer Management of Older Patients by Early and Specific Geriatric Interventions.","Optimization of Care in Older Patients With Cancer Undergoing Treatment in Day Care Unit, Through a Specific Management Based on Early Geriatric Warning Signs: a Multicenter Randomized Trial.","WARNING","Inclusion Criteria:\n\n* Patients aged ≥75 years.\n* Patients with confirmed solid cancer or haematological malignancy, regardless of\n* the site of the tumour (single or multiple), - the duration of the disease, or - the treatment modality (adjuvant, neoadjuvant, locally advanced, palliative metastatic).\n* Patients starting a first line of systemic treatment or a new line of treatment after a break of at least six months.\n* Patients treated in a daycare hospital.\n* Persons belonging to or benefiting from a social security scheme.\n* Free and informed consent after receiving appropriate information.\n\nExclusion Criteria:\n\n* Patients under legal protection (guardianship, curatorship).\n* Persons with enhanced protection, i.e. persons deprived of their liberty by a judicial or administrative decision, persons in a health or social care institution, persons under legal protection and patients in emergency situations.","75 Years",{"count":108,"type":21},1010,[24],"The WARNING project proposes a new care organisation for older patients with cancer. The aim is to optimise management in daycare with early detection signs of geriatric syndromes and specific interventions. This prevention package, called the 'WARNING Pack', includes a specific multimodal geriatric management guide for the oncologist (physician form), based on patient-reported early geriatric warning signs (patient form). Primary outcome is to reduce the risk of deterioration in global quality of life at 6 months during treatment and to prevent the onset of geriatric syndromes.",[112,113],"Neoplasms (Cancer \u002F Tumors)","Geriatric Oncology",{"date":115,"type":33},"2026-07-22",{"date":117,"type":21},"2026-09",{"date":119,"type":21},"2031-01",{"name":39,"class":40},{"id":122,"slug":123,"hasResults":12,"nctId":124,"briefTitle":125,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":12,"sex":128,"minAge":18,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":22,"phases":131,"briefSummary":133,"conditions":134,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":140,"completionDateStruct":141,"leadSponsor":143,"locationsCount":4},"100630656","phase-4-pharmacokinetic-model-of-abemaciclib-correlation-with-severe-diarrhea-as-the-primary-toxicity-endpoint-in-patients-with-localized-hormone-receptor-positive-breast-cancer-100630656","NCT07490509","Pharmacokinetic Model of Abemaciclib: Correlation With Severe Diarrhea as the Primary Toxicity Endpoint in Patients With Localized Hormone Receptor-positive Breast Cancer","DOSABEMA","Inclusion Criteria:\n\n* Women ≥ 18 years old\n* Having breast cancer of all histologies combined\n* Type Luminal A or B with positive hormone receptors (\\>10% expression for estrogen receptor and\u002For progesterone receptor) and HER2 negative or low epidermal growth receptor (according to GEFPICS1 definition)\n* Stage 2 or stage 3 according to the international classification, translated into the SENORIF recommendation\n* Having undergone complete excision surgery (R0 on the invasive tumor and\u002For on the ductal entity in situ) after neoadjuvant chemotherapy or not\n* Defined as high risk of recurrence according to the Monarch-E study, at initial diagnosis of the disease: either ≥ 4 affected axillary lymph nodes (≥N2 involvement), or 1-3 affected axillary lymph nodes (≥N1 involvement) associated with an Elston Ellis grade 3 or a tumor ≥ 5 cm\n* Initiation of adjuvant treatment with abemaciclib in combination with hormone therapy\n* Patient ECOG performance status between 0 and 2\n* Patients with a neutrophil count (NCC) defined as normal prior to the first dose of abemaciclib, i.e., an absolute NCC ≥ 1500\u002F mm3 (≥ 1.5 x 109\u002FL) without granulocyte colony-stimulating factor (GCSF) injection within 15 days prior to laboratory testing, as well as a platelet count ≥ 100,000\u002Fmm3 and a hemoglobin level ≥ 8g\u002FdL.\n* Patient with the psychological and mental capacity to understand the protocol and sign the consent form independently\n* Must be affiliated with the social security system or receive benefits through a third party\n* Have signed the study consent form after reading the information sheet\n\nExclusion Criteria:\n\n* Hypersensitivity to any of the excipients listed in section 6.1 of the abemaciclib (Verzenios) SPC\n* History of treatment with an anti-CDK4\u002F6 (palbociclib, ribociclib, abemaciclib) for any indication\n* History of invasive cancer of any histology within the last 2 years, except for superficial skin tumors, not considered to be in complete remission\n* Presence of functional or inflammatory colorectal disease (Crohn's disease, ulcerative colitis) causing chronic diarrhea (as defined by the WHO as at least 3 bowel movements per day and\u002For liquid stools for at least 1 month)\n* Patient who has undergone total gastrectomy or suffers from short bowel syndrome\n* Patient unable to sign the consent form for societal reasons (illiteracy) or somatic reasons (central nervous system disease).\n* Persons benefiting from enhanced protection, namely minors, persons deprived of their liberty by judicial or administrative decision, persons staying in a health or social care institution, adults under legal protection, and finally patients in emergency situations.\n* Pregnant or breastfeeding women, women of childbearing age who are not using highly effective contraceptive methods (e.g., double-barrier contraception) during treatment and for at least 3 weeks after stopping treatment (The duration of contraception required for concomitant treatments, if any, should also be taken into account.)","FEMALE",{"count":130,"type":21},235,[132],"PHASE4","Remarkable progress has recently been made in the treatment of locally advanced, hormone receptor-positive, HER2-negative breast cancer with a high risk of recurrence, thanks to the addition of abemaciclib to endocrine therapy. This combination has led to a significant improvement in invasive disease-free survival. However, despite the combination's acceptable safety profile, 38% of patients experience grade 3 or higher diarrhea, and 23% experience grade 3 or higher neutropenia. This toxicity can lead to the premature discontinuation of treatment, limiting the benefits of this molecule. As with all oral therapies, the pharmacokinetics of abemaciclib lie at the intersection of efficacy and toxicity and can be modified by several external factors.\n\nThe hypothesis of the study is that abemaciclib's toxicity is correlated with its plasma levels and that its concentration is modified by certain patient characteristics. To this end, a pharmacokinetic model of abemaciclib could be developed using a prospective, multicenter, real-world blood dosage study. This study will describe the relationship between abemaciclib concentration and diarrhea and severe neutropenia, as classified by CTCAE, as well as potential clinical and drug interactions.\n\nIt is hoped that this model demonstrates the importance of monitoring abemaciclib concentrations. This could lead to a therapeutic trial in which the abemaciclib dose is adjusted according to concentration to limit toxicity while maintaining efficacy.",[135,136,137],"Abemaciclib","Abemaciclib-related Diarrhea","Breast Cancer","2026-07-20",{"date":90,"type":33},{"date":117,"type":21},{"date":142,"type":21},"2029-09",{"name":39,"class":40},{"id":145,"slug":146,"hasResults":12,"nctId":147,"briefTitle":148,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":151,"targetDuration":153,"studyType":154,"phases":4,"briefSummary":155,"conditions":156,"keywords":159,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":162,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":168},"100606190","what-is-the-role-of-the-exposome-in-pulmonary-hypertension-100606190","NCT07172334","What is the Role of the Exposome in Pulmonary Hypertension","EXPOSPAH","Inclusion Criteria:\n\n* Consent signed by the participant\n* Age ≥ 18 years\n* Free subject, under no legal protection\n* Good understanding of the French language, allowing to answer the questionnaires\n* Patients with pre-capillary PH confirmed by cardiac catheterization (PAPm \\> 20mmHg, PCP ≤ 15 mmHg, RVP \\> 2UW) having had the right diagnostic cardiac catheterization within one year (≤1 year) :\n\n  * Cases: Patients with PAH without associated pathology: idiopathic or heritable, or with features of venous\u002Fcapillary involvement, according to the clinical classification of PH\n  * Controls: Patients with chronic thromboembolic PH (CTEPH, class 4), according to the clinical classification of PH.\n\nExclusion Criteria:\n\n* Patients classified as HTP groups 2, 3 or 5\n* Patients with a diagnosis of PAH associated with a connective tissue disease, HIV, portal hypertension, congenital heart disease, bilharzia, or a drug or toxic cause considered certain according to the international classification (Aminorex, Benfluorex, Carfilzomib, Dasatinib, Dexfenfluramine, Fenfluramine, Methamphetamines, Mitomycin C, adulterated rapeseed oil)\n* Patients with signs of right heart failure requiring amines and\u002For intensive care hospitalization at time of visit (may be included at a later visit)\n* Patients refusing hair sampling or having no hair \\> 2 cm to allow sampling\n* Patients benefiting from enhanced protection, i.e. minors, persons deprived of their liberty by a judicial or administrative decision, persons staying in a health or social establishment, adults under legal protection, and patients in emergency situations",{"count":152,"type":21},150,"1 Day","OBSERVATIONAL","Pulmonary arterial hypertension (PAH) is a rare and incurable disease affecting people of all ages. It is characterized by obstructive remodeling of the small pulmonary arteries, responsible for an increase in pulmonary arterial pressure, leading to right heart failure and death in the absence of treatment. PAH can be associated with a variety of diseases, but around half of all PAH cases are idiopathic or hereditary, and may develop on predisposed terrain following a \"second hit\", as suggested by the identification of PAH cases associated with the use of anorectic drugs, methamphetamine and occupational exposure to organic solvents. No study has systematically analyzed the exposome of patients with PAH, combining environmental and occupational exposures as well as drugs and medications.\n\nThe exposome of patients with PAH without associated causes will be compared with that of patients with another form of pulmonary hypertension (PH), linked to thromboembolic risk factors: chronic thromboembolic PH (CTEPH), which will constitute the control group.",[157,158],"Pulmonary Arterial Hypertension (PAH)","Chronic Thromboembolic Pulmonary Hypertension (CTEPH)",[160,161],"Pulmonary hypertension","Exposome",{"date":115,"type":33},{"date":164,"type":21},"2027-01",{"date":166,"type":21},"2029-01",{"name":39,"class":40},10,{"id":170,"slug":171,"hasResults":12,"nctId":172,"briefTitle":173,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":176,"targetDuration":178,"studyType":154,"phases":4,"briefSummary":179,"conditions":180,"keywords":182,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":195},"100377812","assessment-of-complication-risk-factors-in-a-french-national-cohort-of-asplenic-patients-100377812","NCT04199403","Assessment of Complication Risk Factors in a French National Cohort of Asplenic Patients","SPLEEN","Inclusion Criteria:\n\n* ≥18 year-old\n* With asplenia due to splenectomy, splenic artery embolization or radiotherapy\n\nExclusion Criteria:\n\n* Genetic asplenia including sick cell disease",{"count":177,"type":21},6000,"10 Years","Spleen could have been surgically removed for trauma, cancer, auto-immune disease, or to perform a diagnosis. Spleen could be non-functional due to radiotherapy or splenic artery embolism. These patients are at risks of infectious diseases due to encapsulated bacteria, cancer, and thromboembolism disease. The purpose of this study is to assess complications occurring in French patients without spleen and to implement new diagnostic tools for follow-up.",[181],"Asplenia",[183,184,185,186],"spleen","asplenic patients","splenectomy","asplenia","2026-07-15",{"date":189,"type":33},"2026-07-16",{"date":191,"type":33},"2020-01-09",{"date":193,"type":21},"2040-01",{"name":39,"class":40},12,{"id":197,"slug":198,"hasResults":12,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":22,"phases":206,"briefSummary":207,"conditions":208,"keywords":210,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":223},"100634829","heartlogic-in-patients-with-heart-failure-100634829","NCT07544771","HeartLogic™ in Patients With Heart Failure.","HeartLogic™ Evaluation for Remote Monitoring vs. Office-based Follow-up in Patients With Heart Failure.","HERO","Inclusion Criteria:\n\n1. Patients aged ≥18 years old;\n2. Patients implanted with a cardiac defibrillator for less than 6 months, with or without resynchronization, enabling the HeartLogic™ algorithm;\n3. Patients with a history of HF (left ventricular ejection fraction ≤40%; or at least one episode of clinical HF with NT-proBNP blood concentration ≥450 ng\u002FL);\n4. Patients with New York Heart Association Class II or III HF;\n5. Patient able to comply with the protocol, including Latitude™ transmissions (including adequate connectivity), and study visits.\n6. Patients with compulsory health insurance\n\nExclusion Criteria:\n\n1. Patients not consenting and non-compliant with remote care directions.\n2. Patients with invasive remote HF monitoring device (such as CardioMems);\n3. Patients with a concomitant HF device other than cardiac resynchronization, such as a ventricular assist devices or cardiac contractility modulation devices;\n4. Patients on heart transplant list, or patients with a heart transplant;\n5. Patients with a glomerular filtration rate \\\u003C30 ml\u002Fmin\u002Fm2;\n6. Participation to a concomitant study evaluating management of HF decompensation, or diuretic titration.\n7. Patients enable to consent.\n8. Patients receiving State Medical Aid (Aide Médicale d'Etat).\n9. Pregnant or breastfeeding women.\n10. Persons benefiting from a reinforced protection, namely minors, persons deprived of liberty by a judicial or administrative decision, adults under legal protection, and finally patients in emergency situations",{"count":205,"type":21},578,[24],"This randomized, multicenter clinical trial will evaluate whether remote management guided by the HeartLogic™ algorithm improves outcomes compared with traditional face-to-face follow-up in adult patients with heart failure recently implanted with a HeartLogic™-enabled ICD or CRT-D device. The primary objective is to determine whether this strategy reduces, at 12 months, the proportion of patients with death, unscheduled hospitalization for heart failure, or deterioration in quality of life. Secondary objectives include assessment of hospitalization, mortality, quality of life, safety, and cost-effectiveness.",[209],"Heart Failure",[61,211,212,213,214],"implantable cardioverter defibrillator","remote monitoring","hospitalization","quality of life","2026-06-19",{"date":217,"type":33},"2026-06-24",{"date":219,"type":33},"2026-04-29",{"date":221,"type":21},"2029-05-15",{"name":39,"class":40},15,{"id":225,"slug":226,"hasResults":12,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":230,"eligibilityCriteria":231,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":232,"targetDuration":4,"studyType":22,"phases":234,"briefSummary":235,"conditions":236,"keywords":238,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":250},"100605745","reducing-burnout-in-healthcare-workers-through-yoga-and-square-breathing-practices-100605745","NCT07166510","Reducing Burnout in Healthcare Workers Through Yoga and Square Breathing Practices","Reducing Burnout in Caregivers Through Yoga and Square Breathing Practices","RESPYR","Inclusion Criteria:\n\n* Subjects aged 18 or over\n* Subjects who have been working for at least one year in the emergency department\u002Femergency medical service\u002Fmobile emergency and resuscitation service of the selected centers as a nursing assistant, paramedic, medical dispatch assistant, registered nurse, or doctor\n* Subjects who are affiliated with or beneficiaries of a social security system\n* Consent signed by the participant regarding their participation in the study\n\nExclusion Criteria:\n\n* Physical or psychological contraindications to practicing yoga or mindfulness meditation.\n* Subjects who reported having been on sick leave for at least three months due to burnout prior to inclusion in the study\n* Subjects who reported currently being monitored and\u002For treated by a healthcare professional for burnout\n* Subjects who reported practicing yoga or meditation regularly (more than one day per week over the last three months)\n* Scheduled absence of at least 3 months (e.g., maternity leave, availability, etc.)\n* Subjects who did not wish to participate in the study.\n* People benefiting from enhanced protection, namely minors, people deprived of their liberty by a judicial or administrative decision, people staying in a health or social care facility, and adults under legal protection.",{"count":233,"type":21},75,[24],"The mental health of healthcare workers, burnout, and the resulting suicides are now described as a real \"public health crisis.\" Emergency departments are not spared by this phenomenon; in fact, up to 71% of emergency physicians suffer from burnout. All professions are affected, with 49.2% of nurses reportedly affected by this phenomenon, and this figure rises to 90.7% of nursing assistants and 30% of paramedics providing advanced life support. However, ensuring the safety and protecting the physical and mental health of workers is a legal obligation in France.\n\nIn their latest recommendation on human factors in critical situations, SFAR experts suggest \"limiting the factors responsible for burnout among caregivers exposed to crisis situations in order to reduce the risk of errors and unprofessional behavior.\" To achieve this, the importance of taking breaks in emergency medicine is already well recognized, and it is recommended that participants be given permission to take care of themselves through an agreement negotiated with peers and other staff members.\n\nFurthermore, for several years now, the benefits of yoga in managing stress among healthcare workers seem to have been confirmed. Yoga is effective in reducing depression and anxiety, and it also improves sleep and clinical performance. It has also been shown to significantly reduce scores on the depersonalization and personal accomplishment items of the Maslach Burnout Inventory (MBI).\n\nIn addition, mindfulness meditation (MPC), based in particular on various breathing techniques including square breathing, is increasingly being studied, and SFAR experts suggest, with the help of these methods in particular, that \"healthcare teams faced with critical situations benefit from psychological preparation for stress management to improve their experience and performance in such critical situations.\" Sudarshan Kriya Yoga, a technique that focuses primarily on breathing rhythm, has also been shown to be effective in improving well-being and reducing burnout among physicians.\n\nFinally, yoga and mindfulness meditation administered together are effective in reducing stress and anxiety among healthcare workers, giving them greater attention, alertness, and ability to manage the stressful demands of work.\n\nHowever, the combination of these two techniques through the implementation of video-guided breaks combining both techniques has never been studied.",[237],"Burn-Out",[239,240,241],"yoga","square breathing","emergency department","2026-06-08",{"date":244,"type":33},"2026-06-09",{"date":246,"type":21},"2026-06",{"date":248,"type":21},"2028-07",{"name":39,"class":40},2,{"id":252,"slug":253,"hasResults":12,"nctId":254,"briefTitle":255,"officialTitle":255,"acronym":256,"eligibilityCriteria":257,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":258,"targetDuration":4,"studyType":22,"phases":260,"briefSummary":261,"conditions":262,"keywords":264,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":41},"100580520","comparison-of-the-effectiveness-of-ultrasound-guided-techniques-and-infrared-illumination-compared-with-the-standard-approach-to-peripheral-venous-line-placement-in-people-with-difficult-venous-access-100580520","NCT06838364","Comparison of the Effectiveness of Ultrasound-guided Techniques and Infrared Illumination, Compared With the Standard Approach to Peripheral Venous Line Placement in People With Difficult Venous Access","REUSSIR-VVP","Inclusion Criteria:\n\n* Patients aged 18 or over\n* Patient with a CT scan appointment and a medical prescription requiring a peripheral venous line.\n* Patient with an A-DIVA score greater than or equal to 2.\n* Patient able and willing to comply with all study procedures.\n* Patient covered by a social security scheme or covered through a third party.\n* Patients who have given their free and informed written consent following clear and fair information about the study.\n\nExclusion Criteria:\n\n* Patient with a contraindication to VVP insertion:\n* Arm with arteriovenous fistula\n* Limb with an orthopaedic or vascular prosthesis\n* Previous mastectomy, axillary lymph node dissection or homolateral radiotherapy of the arm\n* Paralysed limb\n* Presence of haematomas or puncture site wounds\n* Limb with phlebitis or infection\n* Patients already included in the study\n* Persons benefiting from enhanced protection, i.e. minors, persons deprived of their liberty by a judicial or administrative decision, persons staying in a health or social establishment, pregnant or breast-feeding women, adults under legal protection and patients in emergency situations.",{"count":259,"type":21},264,[24],"Introduction\n\nPeripheral venous catheterization (PVC) is the most common invasive procedure in healthcare worldwide. Improving the success rate of PVC on the first attempt is crucial for patients, as it impacts pain, anxiety, the risk of extravasation, rapid access to care, and the patient-provider relationship. For healthcare providers, a higher success rate enhances self-confidence and autonomy, while institutions benefit from improved reputation and reduced costs.\n\nIn the Poitiers hosptial, one in ten catheters is used in imaging services, with CT scan departments accounting for 66.3% of catheter usage due to iodinated contrast injections. Literature suggests two techniques to enhance PVC success: ultrasound-guided and infrared illumination methods. These techniques appear effective primarily for patients with difficult venous access. Additionally, the A-DIVA clinical score has been developed to predict first-attempt success rates. However, no studies in Europe have compared the effectiveness of these two techniques in imaging settings or based on the A-DIVA score. This study aims to identify the most effective technique for PVC in patients with difficult venous access.\n\nObjectives\n\nCompare the proportion of successful PVCs on the first attempt among the classical method (Gold Standard), ultrasound-guided technique, and infrared illumination technique in adult patients with difficult venous access.\n\nCompare the proportion of successful PVCs on the second attempt (if the first attempt fails) among the three techniques.\n\nCompare the total number of attempts required for successful PVC. Evaluate the maximum pain experienced by patients during successful PVC. Assess overall patient satisfaction following successful PVC. Evaluate operator satisfaction with the procedure. Measure the time taken for catheterization from material preparation to successful catheter placement.\n\nAnalyze the fallback strategies chosen by operators after a failed attempt (e.g., calling a colleague, continuing with the classical method, using ultrasound guidance, infrared illumination, or abandoning the procedure).\n\nDescribe the catheter sizes chosen by operators based on the A-DIVA score and the number of failed attempts.\n\nMethodology\n\nThis is a prospective, controlled, randomized, three-arm, single-center, superiority trial involving patients with difficult venous access. Inclusion criteria include:\n\nPatients aged 18 years or older. Patients scheduled for a CT scan requiring PVC. Patients with an A-DIVA score of 2 or higher. Patients capable and willing to comply with study procedures. Patients covered by social security or through a third party. Patients providing written informed consent after receiving clear information about the study.\n\nExclusion criteria include:\n\nPatients with contraindications for PVC (e.g., presence of an arteriovenous fistula, orthopedic or vascular prosthesis, history of mastectomy, etc.).\n\nPatients with contraindications for iodinated contrast injection as defined by the French Society of Radiology.\n\nPatients already included in the study. Vulnerable populations (e.g., minors, pregnant or breastfeeding women, individuals deprived of liberty).\n\nIntervention Groups\n\nControl: Classical method based on clinical examination (visualization and palpation).\n\nExperimental: Ultrasound-guided method. Experimental: Infrared illumination method. Sample Size and Duration\n\nA total of 249 patients will be enrolled, with 82 patients in each group. The inclusion period will last 12 months, and each participant will be involved for a maximum of 4 hours. The total duration of the clinical investigation will be 1 year and 4 hours.\n\nOutcome Measures\n\nThe primary outcome is the proportion of successful PVCs on the first attempt, defined as the administration of 5 ml of NaCl without reported pain or visible edema.\n\nThe total number of skin penetrations by the catheter will be recorded. Maximum pain will be assessed using a numerical rating scale (0-10). Patient satisfaction will be measured using a similar numerical scale. Operator satisfaction will also be evaluated on a scale from 0 (very dissatisfied) to 10 (very satisfied).\n\nTime for catheterization will be recorded in minutes, starting from the preparation of the PVC tray until successful catheter placement.\n\nThe fallback strategy after a failed attempt will be documented. The size of the catheter chosen for each attempt will be recorded. Statistical Analysis\n\nThe primary outcome will be compared among the three groups using ANOVA, followed by pairwise comparisons using Tukey's test if significant differences are found.\n\nExpected Outcomes\n\nIdentifying the most effective PVC technique could increase the likelihood of first-attempt success in adults with difficult venous access.\n\nBenefits for Patients\n\nReduced pain and discomfort from multiple attempts. Decreased risk of infection and extravasation. Maintenance of venous integrity. Sustained trust in the patient-provider relationship.",[263],"Peripheral Venous Catheterization",[265,266,267],"ultrasound guided","infrared","A-DIVA scale","2026-05-27",{"date":270,"type":33},"2026-05-29",{"date":272,"type":33},"2025-04-08",{"date":274,"type":21},"2028-04-08",{"name":39,"class":40},{"id":277,"slug":278,"hasResults":12,"nctId":279,"briefTitle":280,"officialTitle":281,"acronym":282,"eligibilityCriteria":283,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":284,"targetDuration":4,"studyType":22,"phases":286,"briefSummary":287,"conditions":288,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":292,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":298},"100397831","phase-4-clinical-trial-assessing-the-immunogenicity-of-an-anti-pneumococcal-vaccination-strategy-pcv13ppv23-versus-prevenar20-in-adult-patients-treated-for-a-lymphoma-100397831","NCT04460235","Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus PREVENAR20) in Adult Patients Treated for a Lymphoma","Immunogénicité de la Vaccination Anti-pneumococcique (PCV13+PPV23 Versus PREVENAR20) Dans le Lymphome Chez l'Adulte","HEMATOVAC","Inclusion Criteria:\n\n* Patient ≥ 18 year-old.\n* AND medical follow-up in hematology unit\n* AND had received a first course of chemotherapy for diffuse large B cell lymphoma or for follicular lymphoma\n* Life expectancy \\> 6 months.\n* Negative pregnancy test.\n* Having signed the consent form.\n* Having an health insurance.\n\nExclusion Criteria:\n\n* Receiving monoclonal antibodies or biotherapies altering the immune response, other than anti-CD20 antibodies in the chemotherapy protocol.\n* Uncontrolled bacterial, viral or fungal infection less than 7 days.\n* Previous vaccination with PCV13 or PPV23 (unless PCV13 was administered in childhood. The last injection must be performed at least five years ago).\n* Preexisting condition that altered the immune response: splenectomy, HIV, primary or secondary immune deficiency, nephrotic syndrome, sickle cell anemia, autoimmune disorder, solid organ transplantation, immunosuppressive drugs or biotherapy not included in the chemotherapy.\n* Patient who already received chemotherapy for malignancy in the previous 2 years before the inclusion.\n* Major blood clotting disorders preventing intramuscular injection.\n* Medical history of anaphylactic reaction to vaccination.\n* Known allergy to one of the vaccine components.\n* Involvement to another vaccine biomedical research.\n* Protected person.\n* Pregnant women or women of childbearing age without appropriate contraceptive measures.\n* Perfusion of polyvalent immunoglobulins during follow-up.\n* Participants with hypersensitivity to aluminum phosphate, phenol or CRM197 protein, protein derived from Corynebacterium diphtheria.",{"count":285,"type":21},160,[132],"The French Public Health Council recommended pneumococcal vaccination combined strategy for all immunocompromised patients in 2012. This strategy consisted in conjugated 13-valent pneumococcal (PCV13) injection followed 2 months later by polysaccharide 23-valent (PPV23) vaccine injection. In 2024, Health authorities changed guidelines to recommend one injection of PREVENAR20 instead of the 2-vaccine scheme general practitioners are usually in charge of this vaccination. Conjugated pneumococcal vaccine enhances the immunogenicity of the polysaccharide vaccine. Acute leukemia and lymphoma are treated with multiple courses of chemotherapy, impairing the immune system and potentially the response to vaccination. These patients are more at risk for developing pneumococcal invasive diseases than the general population. However, efficacy of pneumococcal vaccination is poorly documented in this setting. We assume that 65% of the patients are non-responders to double compared to 45% for PCV20PREVENAR20 vaccination, according to their anti-pneumococcal immunoglobulin G (Ig) titers and the opsonophagocytic activity (OPA). To assess the immunogenicity of the pneumococcal vaccination combined strategy in adult population of acute leukemia and lymphoma, we will measure anti-pneumococcal serotype-specific IgG titers and OPA at different time-points after completion of the combined vaccine strategy. The primary objective is to assess the immunogenicity of pneumococcal vaccination combined strategy at 3 months after the PCV13 injection (corresponding to 1 month after the end of the combined strategy in cohort A) using Ig G titers and OPA, compared to 3 months post PREVENAR20 (cohort B). At different time points (day 0, 4 weeks post PCV13, and 4 weeks, 3-6 months and 9-12 months post PPV23 and in day 0, 4 weeks post PREVENAR20 and 3 months, 5-8 months and 11-14 months post PREVENAR20, the immunological response to vaccination will be monitored using specific-serotype IgG titers, OPA, and total anti-pneumococcal Ig. We will determine predictive factors of non-response to vaccination by comparing demographic data, biological data and treatment received lymphoma patients. The tolerance and safety of the vaccination strategy will also be assessed in this specific hematological population.",[289,290,291],"Vaccine","Streptococcus Pneumoniae","Lymphoma, Non-Hodgkin",{"date":270,"type":33},{"date":294,"type":33},"2021-09-07",{"date":296,"type":21},"2029-06",{"name":39,"class":40},7,{"id":300,"slug":301,"hasResults":12,"nctId":302,"briefTitle":303,"officialTitle":304,"acronym":305,"eligibilityCriteria":306,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":307,"targetDuration":4,"studyType":22,"phases":309,"briefSummary":310,"conditions":311,"keywords":315,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":320,"completionDateStruct":321,"leadSponsor":323,"locationsCount":4},"100640902","impact-on-prognosis-of-increased-sleep-quality-obtained-by-personalized-night-time-nursing-care-in-critically-ill-patients-100640902","NCT07606495","Impact on Prognosis of Increased Sleep Quality Obtained by Personalized Night-time Nursing Care in Critically Ill Patients","Impact Sur le Pronostic en réanimation d'Une Augmentation du Sommeil Par Soins Nocturnes personnalisés : Essai Clinique randomisé Multicentrique","MEDICOSLEEP","Inclusion Criteria:\n\n* Patients aged 18 years or older admitted to an intensive care unit\n* Conscious patients with a Richmond Agitation-Sedation Scale (RASS) score between -2 and +1\n* Patients without continuous sedation, regardless of ventilatory support\n* No indication for urgent intubation (\\\u003C12 hours)\n* Informed consent from the relatives or the patient himself\n\nExclusion Criteria:\n\n* Brain tumor or neuropsychiatric disorders affecting sleep\n* Amission for stroke or epilepsy\n* Administration of sleep-modifying medication within 24 hours prior to randomization\n* Patients with skin lesions around the central right and left areas preclunding the placement of the electrodes\n* Patients with expected ICU length of stay less than 48 hours\n* Patients with limitation or withdrawal of life-sustaining therapies\n* Patients already included in the study during a previous hospitalization\n* Patients under law protection (guardianship, conservatorship, or judicial protective measures)\n* People under protection (minors, persons deprived of liberty by a judicial or administrative decision, patients in emergency situations)",{"count":308,"type":21},460,[24],"Sleep disturbances are common among intensive care unit (ICU) patients and have been associated with difficult weaning from invasive mechanical ventilation, with an increased risk of endotracheal intubation. Other studies have reported associations between sleep disturbances and prolonged ICU length of stay or the occurrence of delirium. Among the factors contributing to sleep impairment, nighttime care interventions have been identified as a major cause. The management of sleep disorders in the ICU remains complex and often disappointing, and no pharmacological treatment is currently formally recommended. Very recently, a considerable improvement of sleep quantity (+50%) and quality (doubling of deep sleep quantity) has been reported by reorganizing nighttime nursing care according to patients' sleep cycles, using a sleep monitoring medical device.\n\nThe objective of this study is to quantify the impact of a better sleep on prognosis. Sleep will be improved using sleep-guided nursing care during nighttime thanks to a real-time sleep monitor (Sleepscan°).\n\nThe primary endpoint is the proportion of patients requiring invasive mechanical ventilation or who have died at day 7 after inclusion. The main secondary outcomes include the duration of ICU stay, the number of delirium free-days, the score at a discomfort scale, the score at a post-traumatic stress disorder scale at ICU discharge. Intensive care unit-related costs will be assessed.\n\nA multi-sites, prospective, randomized, open-label, superiority trial with two parallel arms will be conducted.\n\nAwake and conscious patients without continuous sedation, regardless of ventilatory support, with no indication for urgent intubation (\\\u003C12 hours) and with an expected ICU length of stay greater than 48 hours will be included.\n\nThe intervention will consist of sleep-guided nighttime nursing care using the Sleepscan monitor from 7:00 p.m. to 7:00 a.m., every night until ICU discharge or day 7. Sleep-guided nursing care consist in postponing non urgent care (such as temperature measurement…) and avoiding entering the room when patients are asleep. Otherwise, when patients are awake, instructions are to go for all care, to cluster and anticipate nursing care and perform comfort care.\n\nIn the control group, sleep will also be recorded using the same device but the tablet will not display the patient's sleep (or awake) status, and nighttime nursing care will be performed according to usual practice and independently of patients' sleep cycles.\n\nBased on our preliminary data and previous studies, it has been estimated that 230 patients per group will be required to detect a reduction in the proportion of patients intubated or deceased at day 7 from 20% in the control group to 10% in the intervention group.\n\nThe intention-to-treat analysis population will include all randomized patients.\n\nDemonstrating an improvement in patient prognosis through enhanced sleep quality would represent a major advancement for intensive care medicine. Reducing the need for invasive mechanical ventilation may lead to shorter ICU stays, lower mortality, fewer post-ICU complications, and reduced hospital costs. Demonstrating an improvement in patient prognosis through enhanced sleep quality would represent a major advancement for intensive care medicine. Reducing the need for invasive mechanical ventilation and the incidence of delirium may lead to shorter ICU stays, lower mortality, fewer post-ICU complications, and reduced hospital costs.",[312,313,314],"Intensive Care Unit (ICU)","Sleep Disruption","Sleep Monitoring",[316,317],"night-time nurse care","sleep promotion","2026-05-26",{"date":270,"type":33},{"date":117,"type":21},{"date":322,"type":21},"2028-06",{"name":39,"class":40},{"id":325,"slug":326,"hasResults":12,"nctId":327,"briefTitle":328,"officialTitle":329,"acronym":330,"eligibilityCriteria":331,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":332,"targetDuration":4,"studyType":154,"phases":4,"briefSummary":334,"conditions":335,"keywords":338,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":344,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":350,"locationsCount":351},"100632733","ventricular-arrhythmias-in-acute-myocardial-infarction-100632733","NCT07517523","Ventricular Arrhythmias in Acute Myocardial Infarction","Ventricular Arrhythmias in the Acute Phase of Myocardial Infarction: ADVERSE MI Study","ADVERSE-MI","Inclusion Criteria:\n\n* ≥ 18 years\n* Acute myocardial infarction\n* Sustained ventricular arrhythmia (ventricular tachycardia or ventricular fibrillation) at the acute phase of an acute myocardial infarction (before hospital discharge)\n* Between January 1, 2012 and April 14, 2024\n\nExclusion Criteria:\n\n* None",{"count":333,"type":21},500,"Ventricular arrhythmias are a serious complication of myocardial infarction. The aim of this study is to provide reliable data on the management and mortality associated with ventricular arrhythmia in the setting of acute myocardial infarction.",[336,337],"Ventricular Arrhythmia","Acute Myocardial Infarction (AMI)",[339,340,341,342,343,211],"ST-segment elevation myocardial infarction","non-ST-segment elevation myocardial infarction","ventricular fibrillation","ventricular tachycardia","cardiac arrest",{"date":345,"type":33},"2026-05-28",{"date":347,"type":33},"2025-06-20",{"date":349,"type":21},"2027-10-01",{"name":39,"class":40},8,{"id":353,"slug":354,"hasResults":12,"nctId":355,"briefTitle":356,"officialTitle":356,"acronym":357,"eligibilityCriteria":358,"healthyVolunteers":359,"sex":17,"minAge":18,"maxAge":360,"enrollmentInfo":361,"targetDuration":4,"studyType":22,"phases":363,"briefSummary":364,"conditions":365,"keywords":368,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":370,"lastUpdatePostDateStruct":371,"startDateStruct":372,"completionDateStruct":374,"leadSponsor":376,"locationsCount":41},"100624439","influence-of-intermittent-hypoxia-on-loop-gain-in-healthy-subjects-100624439","NCT07409649","Influence of Intermittent Hypoxia on Loop Gain in Healthy Subjects","HI-LOOP","Inclusion Criteria:\n\n* Healthy subjects aged 18 to 45\n* BMI between \\[18-25\\] kg\u002Fm2\n* No known sleep disorders\n* Free subjects, not under guardianship or curatorship or subordination\n* Persons affiliated with or beneficiaries of a Social Security scheme\n* Signature of informed consent after clear and honest information about the study\n\nExclusion Criteria:\n\n* Active smoking or cessation within the last 3 months and total consumption \\> 10 pack-years\n* Alcohol or drug addiction\n* Excessive coffee consumption (\\> 3 espressos\u002Fday)\n* History of acute mountain sickness (presence of symptoms such as dizziness, headaches, nausea\u002Fvomiting, and incapacitating fatigue during or after a stay at high altitude)\n* Living at high altitude (above 3,000 meters, continuously for more than 6 months during the last 10 years)\n* History of respiratory and\u002For cardiovascular and\u002For renal and\u002For neurological disease (migraines, epilepsy)\n* Diabetes\n* Anemia, sickle cell anemia\n* Any medication associated with oxygen metabolism and any psychotropic medication (anxiolytics, sedatives, antidepressants, neuroleptics, muscle relaxants, etc.) that may interfere with motor and respiratory control, muscle strength, or sleep quality\n* Women of childbearing age who do not use effective contraception (hormonal\u002Fmechanical: oral, injectable, transcutaneous, implantable, intrauterine device, or surgical: tubal ligation, hysterectomy, total ovariectomy)\n* Concurrent participation in another clinical research study affecting respiratory control or respiratory muscles\n* Persons benefiting from enhanced protection, namely minors, persons deprived of their liberty by judicial or administrative decision, persons staying in a healthcare facility",true,"45 Years",{"count":362,"type":21},40,[24],"Sleep apnoea-hypopnoea syndrome (SAHOS), which causes numerous comorbidities, particularly cardiovascular ones, is widespread worldwide today and incurs significant healthcare costs.\n\nCurrent research in this field focuses on identifying different phenotypes in affected patients in order to provide more personalised treatment.\n\nOne of these phenotypes appears to be linked to instability in ventilatory control due to an increase in loop gain (LG) in these subjects.\n\nHowever, the pathophysiology of this ventilatory control instability due to increased LG is not fully understood. It is still difficult to determine whether subjects have an intrinsically high LG or if exposure to intermittent hypoxia during OSA promotes an increase in LG.\n\nIt has also been demonstrated that OSA causes vascular hyperreactivity by increasing oxidative stress through elevated ROS production. This leads to endothelial dysfunction in response to intermittent hypoxia associated with apnoea. Extracellular vesicles (microvesicles and exosomes) have been shown to play a role in this endothelial response. These extracellular vesicles are essential for intercellular communication in both physiological and pathological situations, such as SAHOS.\n\nTherefore, the objective of this research is to determine whether exposure to intermittent hypoxia and changes in microvesicle phenotype could influence LG, which could lead to new therapeutic advances in the context of SAHOS.",[366,367],"Intermittent Hypoxia","Healthy Volunteers",[369],"loop gain","2026-05-22",{"date":268,"type":33},{"date":373,"type":21},"2026-07",{"date":375,"type":21},"2027-09",{"name":39,"class":40},{"id":378,"slug":379,"hasResults":12,"nctId":380,"briefTitle":381,"officialTitle":382,"acronym":383,"eligibilityCriteria":384,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":385,"targetDuration":4,"studyType":22,"phases":387,"briefSummary":388,"conditions":389,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":392,"lastUpdatePostDateStruct":393,"startDateStruct":394,"completionDateStruct":396,"leadSponsor":397,"locationsCount":41},"100558472","impact-of-a-global-warming-strategy-of-the-patient-on-the-prevalence-of-hypothermia-in-the-recovering-room-100558472","NCT06551558","Impact of a Global Warming Strategy of the Patient on the Prevalence of Hypothermia in the Recovering Room","Impact of a Global Warming Strategy, From the Patient Arrival in the Operating Room to His Discharge From the Recovering Room, Versus a Recommended Management of Intraoperative Warming on the Prevalence of Hypothermia in the Recovering Room","REGLO","Inclusion Criteria:\n\n* Patient undergoing laparoscopic visceral surgery under general anesthesia with transition to recovering room\n\nExclusion Criteria:\n\n* Patient undergoing urgent surgery.\n* Presence of pre-existing infection (temperature higher than 38°C when receiving the patient in the hospital ward.\n* Patient with predetermined length of stay in recovering room.",{"count":386,"type":21},174,[24],"50% of patients are hypothermic when they arrive in the recovery room. This hypothermia is potentially at risk for the patient (increases bleeding, risk of infection, risk of cardiac involvement, morbid mortality) and 33,2% steel hypothermic when they discharge from the recovering room. The anesthesia team must prevent these risks through prevention and treatment measures. Currently the majority of patient warming is done only in the operating room, we want to measure the impact of the extension of this warming before and after the surgery on the patient's temperature and on side effects related to hypothermia.",[390,391],"Hypothermia; Anesthesia","Perioperative\u002FPostoperative Complications","2026-05-21",{"date":318,"type":33},{"date":395,"type":33},"2024-11-08",{"date":94,"type":21},{"name":39,"class":40},{"id":399,"slug":400,"hasResults":12,"nctId":401,"briefTitle":402,"officialTitle":403,"acronym":404,"eligibilityCriteria":405,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":406,"targetDuration":4,"studyType":22,"phases":408,"briefSummary":409,"conditions":410,"keywords":412,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":392,"lastUpdatePostDateStruct":418,"startDateStruct":419,"completionDateStruct":421,"leadSponsor":423,"locationsCount":424},"100492031","non-invasive-ventilation-versus-high-flow-nasal-oxygen-in-intensive-care-units-100492031","NCT05686850","Non-Invasive Ventilation Versus High-flow Nasal Oxygen in Intensive Care Units","Non-Invasive Ventilation Versus High-flow Nasal Oxygen for Post-extubation Respiratory Failure in Intensive Care Units: a Multicenter, Randomized, Controlled Trial","VENTILO","Inclusion Criteria:\n\n* Duration of invasive mechanical ventilation of more than 24h in the ICU before extubation.\n* Post-extubation respiratory failure occurring within the first 7 days after extubation (see criteria below). As in several previous studies, post-extubation respiratory failure will be defined by the presence of the 2 following criteria combining a clinical criterion and a blood gas criterion:\n\n  * Clinical criterion persisting for at least 30 minutes: a respiratory rate exceeding 25 breaths per minute or clinical signs of respiratory distress with increased accessory muscle activity.\n  * Blood gas criterion: Hypoxemia defined as PaO2\u002FFiO2 ratio below 150 mm Hg or respiratory acidosis defined as pH below 7.35 units and PaCO2 above 45 mm Hg. For patients under standard oxygen, FiO2 will calculated according to the following formula: FiO2 = 0.21 + 0.03 x (oxygen flow L\u002Fmin).\n* Informed consent from the relatives or the patient himself, or emergency inclusion procedure in case of inability of patient or proxy to give consent.\n\nExclusion Criteria:\n\n* NIV at home\n* ICU admission for peripheral neuromuscular disease type Guillain-Barré syndrome or myasthenia gravis.\n* Upper airway obstruction as main reason for post-extubation respiratory failure\n* Urgent need for reintubation (respiratory or cardiac arrest, respiratory pauses with loss of consciousness or gasping for air, or severe hypoxemia defined as SpO2 lower than 90% despite maximal oxygen support)\n* Altered consciousness (Glasgow coma scale \\\u003C 12)\n* Unplanned extubation (accidental or self-extubation)\n* Do-not-reintubate order at time of respiratory failure\n* Patient previously included in the study\n* People under protection (minors, persons deprived of liberty by a judicial or administrative decision, adults under law protection)\n* Patient not affiliated to health care system.",{"count":407,"type":21},670,[24],"In intensive care units (ICUs), around 20% of patients experience respiratory failure after planned extubation. Nearly 40-50% of them eventually require reintubation with subsequently high mortality rates reaching 30-40%. NIV used as rescue therapy to treat post-extubation respiratory failure could increase the risk of death. However, NIV may avoid reintubation in a number of cases, and recent large-scale clinical trials on extubation have shown that around 40 to 50% of patients with post-extubation respiratory failure are actually treated with NIV. Whereas high-flow nasal oxygen has never been specifically studied for management of post-extubation respiratory failure, this respiratory support could also in this setting constitute an alternative to standard oxygen or NIV. Given the best noninvasive respiratory support strategy in patients with post-extubation respiratory failure remains unknown, we have decided to assess whether NIV alternating with high-flow nasal oxygen as compared to high-flow nasal oxygen alone may decrease mortality of patients in ICUs with post-extubation respiratory failure.",[411],"Post Extubation Respiratory Failure",[413,414,415,416,417],"Respiratory Failure","post-Extubation","Intubation","Non-invasive ventilation","High-Flow nasal oxygen",{"date":318,"type":33},{"date":420,"type":33},"2023-02-02",{"date":422,"type":21},"2028-08-27",{"name":39,"class":40},47,{"id":426,"slug":427,"hasResults":12,"nctId":428,"briefTitle":429,"officialTitle":430,"acronym":431,"eligibilityCriteria":432,"healthyVolunteers":359,"sex":17,"minAge":18,"maxAge":433,"enrollmentInfo":434,"targetDuration":4,"studyType":22,"phases":435,"briefSummary":436,"conditions":437,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":392,"lastUpdatePostDateStruct":440,"startDateStruct":441,"completionDateStruct":443,"leadSponsor":444,"locationsCount":41},"100462909","cytokine-expression-in-psoriasis-patients-with-and-without-joint-involvement-100462909","NCT05307809","Cytokine Expression in Psoriasis Patients With and Without Joint Involvement","Cytokine Expression in Sera, ex Vivo Stimulated Peripheral Blood Mononuclear Cells Culture, and Skin in Psoriasis - Comparison of Patients With and Without Joint Involvement","CYNEPSA","Inclusion criteria:\n\n* For psoriasis patients :\n\n  * Age over 18 years old\n  * Signed informed consent\n  * 5 year old psoriasis at least\n  * At least one skin lesion over 2 cm\n  * Without any articular symptoms\n  * Without any DMARDs\n  * Without anticoagulant treatments or coagulation disease\n  * With normal articular and enthesis sonography\n* For psoriatic arthritis patients :\n\n  * Age over 18 years old\n  * Signed informed consent\n  * Psoriatic arthritis according to CASPAR criteria\n  * Without any DMARDs\n  * Without anticoagulant treatments or coagulation disease\n  * With at least one synovitis at inclusion\n* For controls\n\n  * Age and sex matched with a patient without any rheumatic or dermatologic medical conditions\n  * No treatment with corticosteroïds or non-steroïdial anti-inflammatory drugsAge over 18 years old\n\nExclusion criteria:\n\n▪ For psoriasis patients :\n\n* Joint damage according to CASPAR criteria\n* Echography activity in favor of chronic inflammatory rheumatism\n* For patients and controls:\n* Without social protection rights\n* People under judiciary protection, of less than 18 years old, pregnant woman, breast feeding women, jailed patients.","100 Years",{"count":362,"type":21},[24],"The objective of the resarch is to study the cytokine profile of patients with psoriatic arthritis and psoriasis in order to better understand the pathophysiology of the disease and the contribution of cytokines to the presence or absence of joint involvement. This research will compare cytokines levels in sera, in PBMC culture after LPS or CD3\u002FCD28 agonist antibodies, and in skin biopsy.",[438,439],"Psoriasis","Psoriatic Arthritis",{"date":318,"type":33},{"date":442,"type":33},"2022-08-17",{"date":30,"type":21},{"name":39,"class":40},{"id":446,"slug":447,"hasResults":12,"nctId":448,"briefTitle":449,"officialTitle":449,"acronym":450,"eligibilityCriteria":451,"healthyVolunteers":12,"sex":17,"minAge":452,"maxAge":453,"enrollmentInfo":454,"targetDuration":4,"studyType":22,"phases":456,"briefSummary":457,"conditions":458,"keywords":460,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":392,"lastUpdatePostDateStruct":465,"startDateStruct":466,"completionDateStruct":468,"leadSponsor":470,"locationsCount":41},"100437921","interest-of-the-7-tesla-mri-in-the-diagnosis-of-post-concussion-syndromes-among-patients-with-mild-traumatic-brain-injury-100437921","NCT04982562","Interest of the 7 Tesla MRI in the Diagnosis of Post-concussion Syndromes Among Patients With Mild Traumatic Brain Injury","SPIN","Inclusion Criteria:\n\n* Mild traumatic brain injury with glascow included between 13 and 15, with indication of scan\n* possibilty of performing an MRI at 7 days\n* Patient able to get to MRI at Day 7\n* Free consentement to the study\n* Any measure of guardianship or curatorship , any link of subordination\n\nExclusion Criteria:\n\n* Patient does not hospitalized about head trauma\n* Inhability to move out for run the seven day MRI\n* Contraindication for MRI\n* Patient having already consulted the emergency for head trauma requiring imaging\n* Patients with psychiatric troubles : bipolarity, panic trouble, depressive trouble, schizophrenia\n* Patient already enrolled in the study\n* History of brain, tumor or neurosurgery\n* Untreated or poorly treated chronic vertigo\n* Untreated or poorly treated chronic migraines\n* Claustrophobia\n* BMI \\> 40\n* Refusal of consent to take part of the study\n* No social welfare or inhability to benefit of it by a third party\n* Patients with enhanced protection : minor aged under 18 ; person with freedom restriction by justice decision or administrative ; homeliving in health or social establishment ; adult in legal protection\n* Pregnant and nursing women","20 Years","72 Years",{"count":455,"type":21},100,[24],"We aimed to conduct a prospective longitudinal interventionnal monocentric study to assess the ability of seven tesla MRI to detect diffuses axonal lesions in patients presenting a post concussional syndrom (PCS) at seven days about a mild traumatic brain injury (MTBI). Our first objective was to evaluate the diagnostic performance of seven tesla MRI runned at seven days after MTBI among patients presenting a PCS.",[459],"Post-Concussion Syndrome",[461,462,463,464],"post-concussion Syndrome","diagnosis of 7T MRI in post-concussion syndrom","S100b","mild head trauma",{"date":370,"type":33},{"date":467,"type":33},"2021-06-26",{"date":469,"type":21},"2027-06-13",{"name":39,"class":40},{"id":472,"slug":473,"hasResults":12,"nctId":474,"briefTitle":475,"officialTitle":476,"acronym":477,"eligibilityCriteria":478,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":479,"targetDuration":4,"studyType":22,"phases":481,"briefSummary":482,"conditions":483,"keywords":485,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":392,"lastUpdatePostDateStruct":490,"startDateStruct":491,"completionDateStruct":493,"leadSponsor":495,"locationsCount":41},"100412473","predictive-multimodal-mri-factors-in-subacute-cerebral-artery-occlusiontreated-by-thrombectomy-pimisutt-100412473","NCT04651010","Predictive Multimodal MRI Factors in Subacute Cerebral Artery Occlusiontreated by Thrombectomy (PIMISUTT)","Predictive Multimodal MRI Factors in Subacute Cerebral Artery Occlusiontreated by Thrombectomy (PIMISUTT","PIMISUTT","Inclusion Criteria:\n\n* Patients aged ≥ 18 years old\n* Hospitalized at the Poitiers University Hospital\n* Acute middle cerebral artery occlusion diagnosed by CT-scan or MRI\n* NIHSS score ≥ 6 at admission\n* To be treated by thrombectomy with or without fibrinolysis\n* Written information delivered to the patient or his relatives concerning the study and its benefit and risk\n\nExclusion Criteria:\n\n* Patients or relatives whom a loyal information about the study cannot be given\n* Patient with cognitive impairments before MRI.\n* Patients who cannot undergo MRI because of contraindications\n* Patients too deteriorated to tolerate one hour long exam",{"count":480,"type":21},50,[24],"Our study aims to measure metabolic and functional parameters of the infarcted territory by multimodal cerebral MRI in patients diagnosed with unilateral proximal occlusion of the middle cerebral artery and treated by thrombectomy in order to correlate those parameters to clinical outcome (evaluated by modified Rankin score) at 3 months.\n\nWe aim to find early radiologic predictive factors for favorable clinical outcome in this population of patients.",[484],"Middle Cerebral Artery Acute Ischemic Stroke",[486,487,488,489],"Ischemic stroke","acute middle cerebral artery occlusion","multimodal MRI","thrombectomy",{"date":318,"type":33},{"date":492,"type":33},"2021-11-15",{"date":494,"type":21},"2026-08-15",{"name":39,"class":40},{"id":497,"slug":498,"hasResults":12,"nctId":499,"briefTitle":500,"officialTitle":501,"acronym":4,"eligibilityCriteria":502,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":503,"targetDuration":4,"studyType":22,"phases":504,"briefSummary":505,"conditions":506,"keywords":509,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":514,"lastUpdatePostDateStruct":515,"startDateStruct":517,"completionDateStruct":519,"leadSponsor":521,"locationsCount":41},"100476982","mri-biomarkers-predictive-of-disability-progression-in-patients-with-multiple-sclerosis-100476982","NCT05491031","MRI Biomarkers Predictive of Disability Progression in Patients With Multiple Sclerosis","Evaluation of MRI Biomarkers Predictive of Disability Progression in Patients With Multiple Sclerosis","Inclusion Criteria:\n\n* Age ≥ 18 years,\n* Duration of disease ≤ 25 years,\n* Irreversible disability ≤ 7 (permanent wheelchair use) on the EDSS scale\n\nExclusion Criteria:\n\n* Other progressive neurological disease,\n* Isolated radiologic syndrome (RIS),\n* Severe psychiatric pathology not in balance,\n* Change in dosage, discontinuation or initiation of a psychotropic treatment within the last month,\n* Change in background MS treatment for less than 3 months,\n* A course of corticosteroids (oral or intravenous) for less than one month,\n* Patient with a contraindication to MRI: pregnancy, metallic ocular foreign body (accidental splinters or others), pacemaker, implantable defibrillator, neurostimulator not compatible with MRI 7.0 T, cochlear implants and in general any electronic medical equipment implanted in an irremovable way: metallic cardiac valve, vascular clips (formerly implanted on cranial aneurysm), metallic prosthesis...),\n* Illiterate and non-French speaking patient: patient who is partially or completely unable to read and write French.\n* Patient benefiting from reinforced protection, i.e. minor, subject deprived of liberty by a judicial or administrative decision, subject staying in a health or social establishment, adult under legal protection and finally patient in emergency situation,\n* Pregnant or breastfeeding women, women of childbearing age who do not have effective contraception (hormonal\u002Fmechanical: per os, injectable, transcutaneous, implantable, intrauterine device, or surgical: tubal ligation, hysterectomy, total oophorectomy)",{"count":480,"type":21},[24],"The transition from relapsing-remitting multiple sclerosis to secondarily progressive multiple sclerosis (SPMS) is difficult to identify. Typically, SPMS is diagnosed retrospectively, with a significant delay, on the basis of a clinical history of progressive worsening, independent of relapses. Thus, SPMS is often associated with a considerable period of diagnostic uncertainty.\n\nThe use of ultra-high field imaging can shed light on the mechanisms of disability progression thanks to its better spatial resolution and advanced imaging techniques.\n\nThe new morphological imaging techniques make it possible to visualize chronic inflammatory lesions and to evaluate their evolution. It also allows for the precise measurement of brain atrophy, a reference in the evaluation of neurodegeneration.\n\nMetabolic imaging via proton spectroscopy allows the analysis of several promising cerebral metabolites that can provide information on cellular energy metabolism, mitochondrial function, or oxidative stress, and can help identify tissues at risk of neurodegeneration. Sodium imaging can provide information on axonal energy metabolism before the occurrence of stable and irreversible axonal damage. This technique is promising as an early marker of neurodegeneration.",[507,508],"Multiple Sclerosis","Magnetic Resonance Spectroscopy",[510,511,512,513],"Multiple sclerosis","ultra-high field 7T magnetic resonance spectroscopy","sodium imaging","predictive MR biomarker of MS","2026-05-04",{"date":516,"type":33},"2026-05-05",{"date":518,"type":33},"2023-04-25",{"date":520,"type":21},"2030-05-01",{"name":39,"class":40},{"id":523,"slug":524,"hasResults":12,"nctId":525,"briefTitle":526,"officialTitle":526,"acronym":527,"eligibilityCriteria":528,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":529,"targetDuration":4,"studyType":22,"phases":530,"briefSummary":531,"conditions":532,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":514,"lastUpdatePostDateStruct":538,"startDateStruct":540,"completionDateStruct":542,"leadSponsor":544,"locationsCount":41},"100386546","virtual-biopsy-development-to-identify-patients-glioma-grade-at-the-chu-of-poitiers-using-magnetic-resonance-imaging-100386546","NCT04313140","Virtual Biopsy Development to Identify Patient's Glioma Grade at the CHU of Poitiers Using Magnetic Resonance Imaging","MR3TGLIOBIOPSY","Inclusion Criteria:\n\n* Age≥ 18 years,\n* Patient with suspected glioma with prior imaging\n* Subject free, with legal protection guardianship or curatorship;\n* Enrollment in the French Social Security system;\n* Informed consent signed by the patient\n\nExclusion Criteria:\n\n* Any contraindication to an MRI examination\n* Legal protection, namely minors, persons deprived of their liberty by a judicial or administrative decision, persons residing in a health or social establishment, adults under legal protection and finally patients in emergency situations\n* Pregnant or lactating women, women of childbearing age who do not have effective contraception",{"count":333,"type":21},[24],"Glioma is a tumor of the central nervous system. These lesions are sorted with the WHO ranking regarding the tumoral oncotype. The tumoral MRI assessment is the first step before any medical decision. Currently, only anatomical biopsy can give the tumor grade definition and help to define the most adapted treatment.",[533,534,535,536,537],"Development of the Virtual Biopsy","Tumor Grade","Artificial Intelligence Algorithms","Clinical","Radiological",{"date":539,"type":33},"2026-05-08",{"date":541,"type":33},"2021-02-22",{"date":543,"type":21},"2029-02",{"name":39,"class":40},{"id":546,"slug":547,"hasResults":12,"nctId":548,"briefTitle":549,"officialTitle":549,"acronym":550,"eligibilityCriteria":551,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":552,"targetDuration":4,"studyType":22,"phases":554,"briefSummary":555,"conditions":556,"keywords":560,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":562,"lastUpdatePostDateStruct":563,"startDateStruct":565,"completionDateStruct":567,"leadSponsor":569,"locationsCount":223},"100628616","relevance-of-the-urine-bacterial-culture-performed-before-transurethral-resection-of-the-bladder-for-post-operative-febrile-urinary-tract-infections-prevention-a-non-inferiority-randomized-controlled-trial-100628616","NCT07463963","Relevance of the Urine Bacterial Culture Performed Before TransUrethral Resection of the Bladder for Post-operative Febrile Urinary Tract Infections Prevention: a Non-inferiority Randomized Controlled Trial","RUPTURE","Inclusion Criteria:\n\n* Patient aged 18 or over\n* Scheduled for TURB surgery for a suspected or confirmed diagnosis of bladder tumor\n* Affiliated person or beneficiary of a social security scheme\n* Written informed consent obtained from the participant\n\nExclusion Criteria:\n\n* Patient with active UTI\n* Planned combined surgery\n* Patient previously included in this research protocol\n* People benefiting from enhanced protection, namely minors, people deprived of their liberty by judicial or administrative decision, people staying in a health or social institution, adults under legal protection\n* Pregnant or breastfeeding women, women of childbearing age who do not have effective contraception (Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation : oral, intravaginal, transdermal; Progestogen-only hormonal contraception associated with inhibition of ovulation : oral, injectable, implantable; Intrauterine device; Intrauterine hormone-releasing system; Bilateral tubal occlusion) or permanent sterilization methods ( hysterectomy, bilateral salpingectomy, bilateral oophorectomy).",{"count":553,"type":21},2600,[24],"The main objective of the study is to demonstrate that not performing a systematic UC before the TURB procedure is non-inferior to performing a systematic UC in terms of the incidence of febrile UTIs during the first 30 postoperative days",[557,558,559],"Bladder Cancer","Transurethral Resection of the Bladder","Urinary Tract Infection Bacterial",[561],"Urine Culture","2026-04-24",{"date":564,"type":33},"2026-04-30",{"date":566,"type":21},"2026-05-15",{"date":568,"type":21},"2030-08-15",{"name":39,"class":40},{"id":571,"slug":572,"hasResults":12,"nctId":573,"briefTitle":574,"officialTitle":575,"acronym":576,"eligibilityCriteria":577,"healthyVolunteers":12,"sex":17,"minAge":106,"maxAge":4,"enrollmentInfo":578,"targetDuration":4,"studyType":154,"phases":4,"briefSummary":580,"conditions":581,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":586,"lastUpdatePostDateStruct":587,"startDateStruct":589,"completionDateStruct":591,"leadSponsor":593,"locationsCount":41},"100629497","prognostic-factors-of-hospitalization-for-patients-aged-75-and-over-in-emergency-department-in-france---monocentric-retrospective-cohort-study-100629497","NCT07475442","Prognostic Factors of Hospitalization for Patients Aged 75 and Over in Emergency Department in France - Monocentric Retrospective Cohort Study","Prognostic Factors of Hospitalization for Patients Aged 75 and Over in Emergency Department in France - Monocentric Retrospective Cohort Study - PROFACTHOS","PROFACTHOS","Inclusion Criteria:\n\n* Adult over or equal 75 years old\n* Patient admitted to the emergency department between 10\u002F01\u002F2022 and 09\u002F30\u002F2023 for the second group, and between 10\u002F01\u002F2024 and 09\u002F30\u002F2025 for the first group\n* Patient and\u002For family and\u002For trusteeship who doesn't refused to participate\n\nExclusion Criteria:\n\n* Patient died before admitted to emergency department\n* Patient already included in the study\n* File created by mistake, identified by the mention \"Erreur de dossier\"\n* Patient deprived of total or partial liberty by a judicial or administrative decision",{"count":579,"type":21},967,"A geriatric patient is defined as a patient aged 75 and over who meets certain medical or social vulnerability criteria and is characterised by coexisting physical and\u002For psychological dependence. The proportion of patients with a geriatric profile in the general population is growing. The average time spent in the emergency department by the elderly population is about 3 hours longer than for patients under 75 years old in France, which is associated with the risk of decompensation of chronic conditions, confusion, falls or agitation. An overnight stay in the emergency department for these patients increases the risk of mortality and the length of hospital stay.\n\nSeveral prognostic scores for hospitalization have been studied in adult populations. The most widely used scores are the Sydney Triage to Admission Risk Tool (START), the Ambulatory (AMB) and the Glasgow Admission Prediction Score (GAPS). Studies have compared these three scores and demonstrated the greater robustness of GAPS. The CalcuLation of the Elderly Admission Risk in the Emergency Department (CLEARED) tool, developed for the elderly population, has lower performance than GAPS. A systematic review of the literature studied the power of GAPS for the geriatric population and highlighted the need for validation in the target population. No validated hospitalization prognostic score was found in France for this population. The research hypothesis is that GAPS would detect hight probability of admission at the time of triage for the patients aged 75 and over in emergency department in France. The primary objective of this monocentric study is to evaluate the prognostic performance of GAPS for the target population (on the group 1). The secondary objectives consist of developing and internally validating a new score (PROFACTHOS) (on the group 2), then performing a temporal validation of PROFACTHOS with comparison to the GAPS (on the group 1), and finally to determine the threshold for classifying patients with a high probability of hospitalization for the score with the strongest discriminatory performance among GAPS or PROFACTHOS.\n\nGroup 1: Patients aged 75 and over admitted to emergency department from 10\u002F01\u002F2024 to 09\u002F30\u002F2025.\n\nGroup 2 : Patients aged 75 and over admitted to emergency department from 10\u002F01\u002F2022 to 09\u002F30\u002F2023",[582,583,584,585],"Elderly","Emergency Departments","Prognostic Factors","Hospitalizations","2026-03-10",{"date":588,"type":33},"2026-03-16",{"date":590,"type":21},"2026-03-15",{"date":592,"type":21},"2027-04-15",{"name":39,"class":40},{"id":595,"slug":596,"hasResults":12,"nctId":597,"briefTitle":598,"officialTitle":599,"acronym":600,"eligibilityCriteria":601,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":602,"targetDuration":4,"studyType":22,"phases":604,"briefSummary":605,"conditions":606,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":608,"lastUpdatePostDateStruct":609,"startDateStruct":611,"completionDateStruct":613,"leadSponsor":615,"locationsCount":250},"100593304","comparison-of-two-ventilation-methods-during-endoscopy-of-the-pharynx-larynx-and-oesophagus-100593304","NCT07004699","Comparison of Two Ventilation Methods During Endoscopy of the Pharynx, Larynx and Oesophagus","OPTIGO \u002FComparison of Two Ventilation Methods During Endoscopy of the Pharynx, Larynx and Oesophagus: Multicentre, Randomised, Non-inferiority Trial","OPTIGO","Inclusion Criteria:\n\n* Patient aged 18 or over.\n* Not requiring oxygen.\n* About to undergo exclusive Endoscopy of the pharynx, larynx and oesophagus surgery.\n* Score de l'American Society of Anesthesiology between 1 and 4\n* Informed consent signed\n\nExclusion Criteria:\n\n* Endoscopy of the pharynx, larynx and oesophagus surgery combined with another procedure\n* Severe or morbid obesity (BMI ≥ 35 kg\u002Fm²)\n* Patients with stage IV chronic obstructive pulmonary disease\n* Allergy to one of the drugs used in anaesthesia, remifentanil and\u002For propofol and\u002For lidocaine.",{"count":603,"type":21},610,[24],"Around 15,000 ENT cancers are diagnosed each year in France. The majority of these cancers will at one time or another require an Endoscopy of the Pharynx, Larynx and Esophagus (Endo-PLE or suspension laryngoscopy). Endoscopies of the Otorhinolaryngeal (ENT) sphere are common procedures. They consist of inserting a rigid laryngoscope through the mouth, allowing full exposure of the laryngeal sphere. They are performed in most cases as part of a swelling assessment, following CT scans, or following the discovery of a mass upon palpation of the patient. Unfortunately, these are aggressive cancers that subsequently require major surgery and additional treatment by radio or chemotherapy. This examination can also be performed on patients suffering from swallowing disorders, following the appearance of polyps, and this time not requiring an adjuvant to surgery but their removal. For all patients, these endo-PLE are performed in the operating room and require general anesthesia. This surgical procedure is now performed by performing two laryngoscopies. The first is used to maintain good pulmonary oxygenation by introducing an oxygen cannula, the second constitutes the surgical procedure itself. The oxygen cannula is placed through the nasal cavity, directly up to the entrance of the vocal cords. This procedure is not without risk both for the patient (risk of dental breakage and bleeding during laryngoscopy) but also for the surgeon, because the cannula itself can obstruct his vision. It would be possible to do without one of them by setting up high-flow oxygen therapy (HFOT). This device has been widely deployed in continuous care and intensive care units, but is not yet the subject of much research in surgical units. The HFOT consists of oxygen cannulae delivering a mixture of gases at a high flow rate ranging from 20 to 70 liters per minute. The investigator want to evaluate through this study, the feasibility and effectiveness of setting up HFOT during procedures. The evaluation of this benefit compared to the standard method will be done using several elements including the collection of continuous saturation and blood analysis of capillary samples pre-, per- and post-operatively.",[607],"Oxygen Inhalation Therapy Endoscopy","2026-02-25",{"date":610,"type":33},"2026-02-27",{"date":612,"type":33},"2025-07-11",{"date":614,"type":21},"2027-07-01",{"name":39,"class":40},{"id":617,"slug":618,"hasResults":12,"nctId":619,"briefTitle":620,"officialTitle":621,"acronym":622,"eligibilityCriteria":623,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":624,"targetDuration":4,"studyType":22,"phases":626,"briefSummary":627,"conditions":628,"keywords":632,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":638,"lastUpdatePostDateStruct":639,"startDateStruct":640,"completionDateStruct":642,"leadSponsor":644,"locationsCount":298},"100571913","evaluation-of-percutaneous-cryoneurotomy-compared-to-surgical-open-neurotomy-for-the-management-of-equinovarus-foot-deformity-in-patients-with-refractory-lower-limb-spasticity-after-stroke-100571913","NCT06726434","Evaluation of Percutaneous Cryoneurotomy Compared to Surgical Open Neurotomy for the Management of Equinovarus Foot Deformity in Patients With Refractory Lower Limb Spasticity After Stroke","Evaluation of Percutaneous Cryoneurotomy Compared to Surgical Open Neurotomy for the Management of Equinovarus Foot Deformity in Patients With Refractory Lower Limb Spasticity After Stroke: a Multicenter, Randomized Controlled, Non-inferiority Trial","CRYOSTROKE","Inclusion Criteria:\n\n* Age ≥18 years old.\n* Patient with spastic equinovarus foot as a result of stroke in chronic phase (\\>6 months).\n* Patient with positive perineural motor block test with or without complete correction of spastic equinus and non-persistence of 40° equinus.\n* Patient eligible for surgical neurotomy for varus equinus foot.\n* Patient presenting no cognitive impairment or major depression (Mini Mental State Examination\\>20, Hospital Anxiety and Depression (HAD\\\u003C11)).\n* Absence of active psychosis or history of serious psychotic illness requiring hospitalization\n* Patient understanding and accepting the constraints of the study.\n* Patient covered by French national health insurance.\n* Patient who has given their written consent to the study after having received clear information.\n\nExclusion Criteria:\n\n* Patient with previous nerve procedures such as chemical neurolysis with alcohol, cryoneurotomy, or any surgery at the same anatomical site.\n* Patient with any neurological pathology different from the one responsible for the spasticity.\n* Patient with botulinum toxin in lower limb injection during the last 90 days before intervention.\n* Patient with anti-spastic treatment (baclofene) up 3 days before block test.\n* Patient with total deficit of valgus muscles.\n* Patient with equinus foot \\> 40° (retractions\u002Fankylosis).\n* Surgical and anesthetic contra-indications (severe uncontrolled coagulation disorder, active infection).\n* Cryoneurotomy contra-indications (cold intolerance, cryoglobulinemia, cryofibrinogenemia, Raynaud's phenomena, venous thromboemolism (\\\u003C 3 months if superficial, \\\u003C 6 months if deep), hypothyreosis, cold urticari, local disorders of blood supply, considerable anemia, cachexia, hypothermia, cancer disease, infection, coagulopathy…).).\n* Subject requiring closer protection, i.e. minors, pregnant women, nursing mothers, subjects deprived of their freedom by a court or administrative decision, subjects admitted to a health or social welfare establishment, major subjects under legal protection (temporary or permanent guardianship and, subject to subordination), and finally patients in an emergency setting.\n* Pregnant woman, nursing mother, woman of childbearing potential not using effective contraception (hormonal\u002Fbarrier: oral, parenteral, percutaneous, implantable, intrauterine device, or surgical: tubal ligation, hysterectomy, total ovariectomy).",{"count":625,"type":21},114,[24],"CRYOSTROKE study is designed :\n\n* to compare the efficacy and safety of percutaneous CryoNeurotomie (CN) versus surgical neurotomy (SN) on spasticity, 90 days after intervention, in post-stroke patients presenting with spastic equinovarus foot and,\n* to ensure that potential clinical effect\u002Fsafety remain stable within time, with a 12-month follow-up.",[629,630,631],"Stroke","Equinovarus Foot","Refractory Lower Limb Spasticity",[633,634,635,636,637],"surgical neurotomy","CryoNeurotomy","spasticity","cryoneurolysis","percutaneous cryoneurolysis","2026-02-24",{"date":608,"type":33},{"date":641,"type":33},"2025-07-09",{"date":643,"type":21},"2029-06-09",{"name":39,"class":40},""]